Novartis appoints John Tsai as Head of Global Drug Development and CMO

Basel, April 19, 2018 – Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and will be based in Basel, Switzerland. He will report to Vas Narasimhan, M.D., CEO of Novartis and will become a member of the Executive Committee of Novartis (ECN). He succeeds Dr. Narasimhan who became CEO of Novartis on February 1, 2018. Dr. Rob Kowalski, who led GDD ad interim since February 1, 2018, will resume his responsibilities as Head of Global Regulatory Affairs for GDD.

Dr. Tsai has been Chief Medical Officer and Senior Vice President of Global Medical at Amgen Inc., since May 2017 and oversees all clinical and medical functions across multiple sites worldwide. At Novartis, he will be responsible for advancing the company’s industry-leading pipeline of innovative medicines and biosimilars. Dr. Tsai will also lead the GDD organization’s ongoing transformation embracing the power of advanced data sciences and digital technologies to create a more agile model for drug development.

“I am delighted to welcome John to Novartis,” said Dr. Narasimhan. “As we continue to reimagine drug development, his expertise across multiple therapeutic areas, including cardiovascular, oncology and neuroscience combined with his background in electrical engineering will be a source of great strength for Novartis. John has a great track record in nurturing talent across clinical development, medical affairs and development operations and shares our commitment to build an empowered and inspired organization. I also want to express my sincere gratitude to Rob Kowalski for his excellent ad interim leadership of the GDD organization.”

  • Related Posts

    • Pharma
    • June 16, 2025
    • 97 views
    Natco API plant gets one observation from FDA

    Hyderabad: Drugmaker, Natco Pharma, Mekaguda-based Active Pharmaceutical Ingredients (API) plant has received one observation under the form 483 from the US Food and Drug Administration (FDA). In a stock exchange…

    • Pharma
    • June 16, 2025
    • 85 views
    Pharma department refuses to name 30 doctors in bribery tangle

    Thirty doctors who accepted foreign travel and hospitality worth Rs 1.9 crore from pharma company AbbVie in Feb-March 2024 have faced no action from NMC because the department of pharmaceuticals…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco API plant gets one observation from FDA

    Natco API plant gets one observation from FDA

    Pharma department refuses to name 30 doctors in bribery tangle

    Pharma department refuses to name 30 doctors in bribery tangle

    Delhi Police busts fake cancer drugs racket

    Delhi Police busts fake cancer drugs racket

    Sun Pharma appoints Kirti Ganorkar as the Managing Director

    Sun Pharma appoints Kirti Ganorkar as the Managing Director